MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Public ClinicalTrials.gov record NCT05007106. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) With Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.
Study identification
- NCT ID
- NCT05007106
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 613 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab/Vibostolimab Co-Formulation Biological
- Pembrolizumab Biological
- Lenvatinib Drug
- 5-Fluorouracil Drug
- Cisplatin Drug
- Paclitaxel Drug
- Gemcitabine Drug
- Carboplatin Drug
- Docetaxel Drug
- Bevacizumab Drug
- Capecitabine Drug
- Oxaliplatin Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 15, 2021
- Primary completion
- Aug 4, 2025
- Completion
- Aug 4, 2025
- Last update posted
- Aug 13, 2025
2021 – 2025
United States locations
- U.S. sites
- 14
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Womens Cancer Care ( Site 1016) | Anchorage | Alaska | 99508 | — |
| City of Hope Comprehensive Cancer Center ( Site 1001) | Duarte | California | 91010 | — |
| University of California, Irvine (UCI) Health - UC Irvine Me-Chao Family Comprehensive Cancer Cente | Orange | California | 92868-3201 | — |
| Karmanos Cancer Institute ( Site 1007) | Detroit | Michigan | 48201 | — |
| Memorial Sloan Kettering - Basking Ridge ( Site 1023) | Basking Ridge | New Jersey | 07920 | — |
| Memorial Sloan Kettering - Monmouth ( Site 1022) | Middletown | New Jersey | 07748 | — |
| Memorial Sloan Kettering - Bergen ( Site 1025) | Montvale | New Jersey | 07645 | — |
| Memorial Sloan Kettering- Commack ( Site 1021) | Commack | New York | 11725 | — |
| Memorial Sloan Kettering - Westchester ( Site 1020) | Harrison | New York | 10604 | — |
| Memorial Sloan Kettering Cancer Center ( Site 1002) | New York | New York | 10065 | — |
| Memorial Sloan Kettering - Nassau ( Site 1026) | Uniondale | New York | 11553 | — |
| Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1024) | Tulsa | Oklahoma | 74146 | — |
| Sanford Cancer Center-Gynecologic Oncology ( Site 1015) | Sioux Falls | South Dakota | 57104 | — |
| Houston Methodist Hospital ( Site 1017) | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 59 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05007106, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2025 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05007106 live on ClinicalTrials.gov.